Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
Adverum Biotechnologies (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, announced its upcoming participation in the Cowen 45th Annual Healthcare Life Sciences Conference. The company will present on Tuesday, March 4 at 11:50 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Events and Presentations section of Adverum's website. A replay will remain available on the site for at least 30 days after the event.
Adverum is working to establish gene therapy as a new standard of care for highly prevalent ocular diseases, positioning this conference appearance as an opportunity for the company to share updates on its clinical progress and pipeline developments.
Adverum Biotechnologies (Nasdaq: ADVM), un'azienda in fase clinica focalizzata sulla terapia genica per le malattie oculari, ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute e le Scienze della Vita di Cowen. L'azienda presenterà martedì 4 marzo alle 11:50 a.m. ET.
Investitori e parti interessate possono accedere a una trasmissione in diretta della presentazione attraverso la sezione Eventi e Presentazioni del sito web di Adverum. Una registrazione rimarrà disponibile sul sito per almeno 30 giorni dopo l'evento.
Adverum sta lavorando per stabilire la terapia genica come nuovo standard di cura per le malattie oculari altamente prevalenti, posizionando questa partecipazione alla conferenza come un'opportunità per l'azienda di condividere aggiornamenti sui suoi progressi clinici e sviluppi del pipeline.
Adverum Biotechnologies (Nasdaq: ADVM), una empresa en etapa clínica centrada en la terapia génica para enfermedades oculares, anunció su próxima participación en la 45ª Conferencia Anual de Salud y Ciencias de la Vida de Cowen. La empresa presentará el martes 4 de marzo a las 11:50 a.m. ET.
Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la sección de Eventos y Presentaciones del sitio web de Adverum. Una repetición estará disponible en el sitio durante al menos 30 días después del evento.
Adverum está trabajando para establecer la terapia génica como un nuevo estándar de atención para las enfermedades oculares altamente prevalentes, posicionando esta aparición en la conferencia como una oportunidad para que la empresa comparta actualizaciones sobre su progreso clínico y desarrollos en su pipeline.
Adverum Biotechnologies (Nasdaq: ADVM)는 안과 질환을 위한 유전자 치료에 초점을 맞춘 임상 단계 기업으로, 코웬 제45회 연례 헬스케어 생명과학 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사는 3월 4일 화요일 오전 11시 50분 ET에 발표할 예정입니다.
투자자 및 관심 있는 분들은 Adverum 웹사이트의 이벤트 및 발표 섹션을 통해 발표의 웹캐스트에 접근할 수 있습니다. 이벤트 후 최소 30일 동안 웹사이트에서 다시 시청할 수 있습니다.
Adverum은 유전자 치료를 매우 흔한 안과 질환에 대한 새로운 치료 표준으로 확립하기 위해 노력하고 있으며, 이 컨퍼런스 참여를 통해 회사의 임상 진행 상황 및 파이프라인 개발에 대한 업데이트를 공유할 기회로 삼고 있습니다.
Adverum Biotechnologies (Nasdaq: ADVM), une entreprise en phase clinique axée sur la thérapie génique pour les maladies oculaires, a annoncé sa prochaine participation à la 45ème Conférence Annuelle sur la Santé et les Sciences de la Vie de Cowen. L'entreprise présentera le mardi 4 mars à 11h50 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire de la présentation via la section Événements et Présentations du site web d'Adverum. Un replay sera disponible sur le site pendant au moins 30 jours après l'événement.
Adverum travaille à établir la thérapie génique comme un nouveau standard de soins pour les maladies oculaires très répandues, positionnant cette apparition à la conférence comme une opportunité pour l'entreprise de partager des mises à jour sur ses progrès cliniques et ses développements de pipeline.
Adverum Biotechnologies (Nasdaq: ADVM), ein Unternehmen in der klinischen Phase, das sich auf Gentherapie für Augenkrankheiten konzentriert, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Cowen angekündigt. Das Unternehmen wird am Dienstag, den 4. März um 11:50 Uhr ET präsentieren.
Investoren und interessierte Parteien können über den Bereich Veranstaltungen und Präsentationen auf der Website von Adverum auf einen Webcast der Präsentation zugreifen. Eine Wiederholung wird mindestens 30 Tage nach der Veranstaltung auf der Seite verfügbar sein.
Adverum arbeitet daran, Gentherapie als neuen Standard der Versorgung für hochprävalente Augenkrankheiten zu etablieren, und positioniert diesen Auftritt auf der Konferenz als Gelegenheit, um Updates zu seinen klinischen Fortschritten und Pipeline-Entwicklungen zu teilen.
- None.
- None.
REDWOOD CITY, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on Tuesday, March 4 at 11:50 a.m. ET.
The webcast of the presentation may be accessed under Events and Presentations in the Investors section of Adverum’s website. A replay of the webcast will be available on the website for at least 30 days following the event.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
FAQ
When is Adverum Biotechnologies (ADVM) presenting at the Cowen Healthcare Conference?
How can investors access ADVM's presentation at the Cowen conference?
What is Adverum Biotechnologies' (ADVM) primary focus area?
What stock exchange is ADVM listed on?
Where is Adverum Biotechnologies headquartered?
